Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.

US stock futures edged higher Thursday ahead of a highly-anticipated speech by Fed chair Jerome Powell, which could provide ...

Merck , known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Each year, 500 to 1,000 people in the U.S. are diagnosed with pulmonary arterial hypertension (PAH), a progressive and often under-detected disease. To address the significant impact of this disease ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Chemical maker Dow (NYSE: DOW) is one of the smaller companies on the Dow Jones Industrial Average at a market cap of just ...

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest ...

Each year, 500 to 1,000 people in the United States are diagnosed with pulmonary arterial hypertension (PAH). Because this progressive, chronic disorder is rare, it is often under-detected, causing ...

Keytruda has been a top-selling drug for years, generating billions in revenue for Merck -- a company whose market cap of $270 billion is nearly 17 times more valuable than Summit, even with the ...

Keytruda has been a top-selling drug for years, generating billions in revenue for Merck -- a company whose market cap of $270 billion is nearly 17 times more valuable than Summit, even with the ...